Browse Technologies

Displaying 21 - 30 of 32


Natural product for seizure relief and long term disease modification in Dravet Syndrome

Dravet syndrome is a lifelong form of epilepsy beginning in early childhood. Children with Dravet syndrome suffer aggressive seizures, impaired cognition, and an increased risk of premature death. Dravet syndrome does not respond to conventional anti-epileptic drugs, and current treatment regimens fail to fully elevate seizures. No disease modifying treatments exist. Researchers at Vanderbilt University have discovered a novel application of a known natural product in treating Dravet syndrome. This natural product could be beneficial to children suffering from Dravet syndrome in both reducing seizures and treating the underlying disease cause.


Licensing Contact

Tom Utley

615.343.3852

Inventors

Jingqiong Kang
Therapeutics
Neuroscience/Neurology

Small Molecule-GIRK Potassium Channel Modulators That Are Anxiolytic Therapeutics

The G-protein activated, inward-rectifying potassium (K+) channels, "GIRKs", are a family of ion channels that has been the focus of intense research interest for nearly two decades. GIRK has been shown to play important roles in the pathophysiology of diseases such as anxiety, epilepsy, Down's syndrome, pain perception and drug addiction. Here scientists at Vanderbilt developed the first truly potent, effective, and selective GIRK activator, ML297 (VU0456810) and demonstrated that ML297 is active in animal models of epilepsy. While the group is using ML297 to continue to explore the therapeutic benefits of GIRK modulation, they are continuing to develop more selective and druggable GIRK inhibitors from different scaffolds.


Licensing Contact

Tom Utley

615.343.3852
Therapeutics
Analgesic

Antimicrobial Compounds and Methods of Use Thereof

Vanderbilt researchers, led by Eric Skaar, Ph.D., have identified novel compounds that are antimicrobial. These compounds represent a first in class as they target a new bacterial pathway that has never been targeted as an antimicrobial strategy.


Licensing Contact

Karen Rufus

615.322.4295
Therapeutics

Treating Glioblastoma by a Combination Therapy of Gamma-secretase inhibitors and Farnesyltransferase Inhibitors

Scientists at Vanderbilt have developed a novel therapy for gliobastoma multiform that results in minimal recurrence of the tumor. The therapy combines two inhibitors that effectively compromise tumor cell growth and survival. The therapy can be followed by radiation, a common treatment for cancer cells.


Licensing Contact

Karen Rufus

615.322.4295

Inventors

Jialiang Wang
Therapeutics

Inhibitors of Inward-Rectifying Potassium Channels (Insecticide)

This research targets IRK.


Licensing Contact

Tom Utley

615.343.3852

Plasmid Based Reverse Genetics for Reovirus

Scientists at Vanderbilt have developed an entirely plasmid-based system to better utilize reoviruses as a research tool. The system allows for generating a reovirus entirely from cloned cDNAs comprising three steps involving fairly well-known techniques.


Licensing Contact

Mike Villalobos

615.322.6751

Assay for Novel Serotonin Transporter Blockers

The mutant SERTs we have developed can provide for a platform to screen for novel modes/molecules interrupting SERT function. As SERT blockers are effective antidepressants, this strategy can lead to novel antidepressant medications. It may also be useful in development of animal models to test antidepressant action in vivo.


Licensing Contact

Karen Rufus

615.322.4295

Targeting Notch 3 Receptor Function Using Specific Peptides and Antipeptide Biomolecules

The present invention involves the use of peptides from Notch3, and antibodies that recognize epitopes represented by those peptides, as anti-cancer agents. Methods of combination therapy using standard anti-cancer protocols in conjunction with Notch3 peptides and antibodies also are provided.


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics

Use of mGluR5 Partial Antagonists for the Treatment of Anxiety and Other CNS Disorders

Provided is a method of treating conditions and disorders for which full mGluR5 antagonists are potentially effective, such as, e.g., anxiety, epilepsy, schizophrenia and other psychotic disorders, Parkinson's disease, addictive disorders, and the like in a subject in need of such treatment, comprising administration to such subject of a therapeutically effective amount of a partial, non-competitive mGluR5 antagonist compound of the invention.


Licensing Contact

Tom Utley

615.343.3852

Novel Esters and Amides Derived from Indolealkanol and Indolealkylamines as Selective Cyclooxygenase-2 (Cox-2) Inhibitors

A compound of the formula ##STR1## where: n, and X are as defined in the specification, and the compound possesses selectivity for inhibition of cyclooxygenase-2.


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics
Inflammatory/Immune